Drug interactions between inhaled corticosteroids and enzymatic inhibitors.
Daveluy
Amélie
A
Raignoux
Cécile
C
Miremont-Salamé
Ghada
G
Girodet
Pierre-Olivier
PO
Moore
Nicholas
N
Haramburu
Françoise
F
Molimard
Mathieu
M
D000280:Administration, Inhalation; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D000309:Adrenal Insufficiency / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D002648:Child; D003480:Cushing Syndrome / Q000209:etiology*; D051544:Cytochrome P-450 CYP3A; D065692:Cytochrome P-450 CYP3A Inhibitors; D004110:Diltiazem / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005260:Female; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D017964:Itraconazole / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D019438:Ritonavir / Q000627:therapeutic use; D014700:Verapamil / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents; D065692:Cytochrome P-450 CYP3A Inhibitors; D017320:HIV Protease Inhibitors; D017964:Itraconazole; D014700:Verapamil; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D004110:Diltiazem; D019438:Ritonavir